keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer immunotherapy

keyword
https://www.readbyqxmd.com/read/29146441/combining-immunotherapies-for-the-treatment-of-prostate-cancer
#1
REVIEW
Jason M Redman, James L Gulley, Ravi A Madan
Sipuleucel-T, a therapeutic dendritic-cell vaccine, was Food and Drug Administration-approved for prostate cancer in 2010. No new immunotherapies for prostate cancer have been approved since. However, novel agents and combination approaches offer great promise for improving outcomes for prostate cancer patients. Here we review the latest developments in immunotherapy for prostate cancer. Sipuleucel-T has demonstrated a survival advantage of 4.1 months in metastatic castration-resistant prostate cancer. PSA-TRICOM (PROSTVAC), a prostate-specific antigen-targeted vaccine platform, showed evidence of clinical and immunologic efficacy in early-phase clinical trials, and results from a phase III trial in advanced disease are pending...
December 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29125731/imaging-pd-l1-expression-with-immunopet
#2
Charles Truillet, Hsueh Ling J Oh, Siok Ping Yeo, Chia-Yin Lee, Loc T Huynh, Junnian Wei, Matthew F L Parker, Collin Blakely, Natalia Sevillano, Yung-Hua Wang, Yuqin S Shen, Victor Olivas, Khaled M Jami, Anna Moroz, Benoit Jego, Emilie Jaumain, Lawrence Fong, Charles S Craik, Albert J Chang, Trever G Bivona, Cheng-I Wang, Michael J Evans
High sensitivity imaging tools could provide a more holistic view of target antigen expression to improve the identification of patients who might benefit from cancer immunotherapy. We developed for immunoPET a novel recombinant human IgG1 (termed C4) that potently binds an extracellular epitope on human and mouse PD-L1 and radiolabeled the antibody with zirconium-89. Small animal PET/CT studies showed that (89)Zr-C4 detected antigen levels on a patient derived xenograft (PDX) established from a non-small-cell lung cancer (NSCLC) patient before an 8-month response to anti-PD-1 and anti-CTLA4 therapy...
November 15, 2017: Bioconjugate Chemistry
https://www.readbyqxmd.com/read/29121062/loss-of-function-jak1-mutations-occur-at-high-frequency-in-cancers-with-microsatellite-instability-and-are-suggestive-of-immune-evasion
#3
Lee A Albacker, Jeremy Wu, Peter Smith, Markus Warmuth, Philip J Stephens, Ping Zhu, Lihua Yu, Juliann Chmielecki
Immune evasion is a well-recognized hallmark of cancer and recent studies with immunotherapy agents have suggested that tumors with increased numbers of neoantigens elicit greater immune responses. We hypothesized that the immune system presents a common selective pressure on high mutation burden tumors and therefore immune evasion mutations would be enriched in high mutation burden tumors. The JAK family of kinases is required for the signaling of a host of immune modulators in tumor, stromal, and immune cells...
2017: PloS One
https://www.readbyqxmd.com/read/29109964/immunotherapy-as-a-promising-treatment-for-prostate-cancer-a-systematic-review
#4
REVIEW
Marlena Janiczek, Łukasz Szylberg, Anna Kasperska, Adam Kowalewski, Martyna Parol, Paulina Antosik, Barbara Radecka, Andrzej Marszałek
Prostate cancer treatment is currently based on surgical removal, radiotherapy, and hormone therapy. In recent years, another therapeutic method has emerged-immunological treatment. Immunotherapy modulates and strengthens one's immune responses against cancer. Neoplastic cells naturally escape from the control of the immune system, and the main goal of immune therapy is to bring the control back. Satisfying outcomes after treatment of advanced melanoma and lung cancer suggest a great potential of immunotherapy as an approach for other tumors' treatment, especially in patients primarily introduced to palliative care...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/29095729/prostate-cancer-immunotherapy-where-are-we-and-where-are-we-going
#5
Marco A De Velasco, Hirotsugu Uemura
PURPOSE OF REVIEW: In this review, we present the progress and current landscape for prostate cancer immunotherapy and overview recent scientific findings that shed novel insights into immunoresistance and discuss potential therapeutic strategies. RECENT FINDINGS: Prostate cancer immunogenicity is hampered by a highly immunosuppressive microenvironment and low mutation burden. Complex interactions between resident immunosuppressive cells such regulatory T cells, macrophages, myeloid-derived suppressor cells, and cancer cells cooperate to suppress antitumor immune responses and promote disease progression...
October 31, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/29059776/re-effective-combinatorial-immunotherapy-for-castration-resistant-prostate-cancer
#6
Samir S Taneja
No abstract text is available yet for this article.
November 2017: Journal of Urology
https://www.readbyqxmd.com/read/29056275/current-and-future-applications-of-novel-immunotherapies-in-urological-oncology-a-critical-review-of-the-literature
#7
REVIEW
Berna C Özdemir, Arlene O Siefker-Radtke, Matthew T Campbell, Sumit K Subudhi
CONTEXT: Immunotherapies promote anticancer responses with varying levels of success based on the tumor type. OBJECTIVE: In this narrative review article, we searched the literature regarding immunotherapies in genitourinary malignancies to define the state of the field, explore future applications of immune checkpoint inhibitors, cytokines, vaccines, and cellular therapies in urological oncology and evaluate possible strategies to improve the selection of patients who might benefit from such approaches...
October 19, 2017: European Urology Focus
https://www.readbyqxmd.com/read/29054496/cancer-immunotherapy-a-paradigm-shift-in-the-treatment-of-advanced-urologic-cancers
#8
REVIEW
David M Gill, Neeraj Agarwal
The recent resurgence of immunotherapy has transformed the therapeutic field of advanced urologic cancers. In this seminars issue, we evaluate the role of emerging and recently approved immunotherapeutic agents in advanced prostate, urothelial, and renal cell carcinoma. In each of these fields, we discuss recent regulatory approvals as well as promising ongoing clinical trials. Finally, we discuss incidence and management of immune related adverse events specifically associated with PD-1/PD-L1 inhibitors.
October 17, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29053897/scientists-investigate-the-application-of-immunotherapy-to-many-cancer-sites-breast-and-prostate-cancers-prove-more-challenging-but-progress-is-occurring
#9
https://www.readbyqxmd.com/read/29051161/prostate-cancer-cells-express-more-androgen-receptor-ar-following-androgen-deprivation-improving-recognition-by-ar-specific-t-cells
#10
Brian M Olson, Melissa Gamat, Joseph Seliski, Thomas Sawicki, Justin Jeffery, Leigh Ellis, Charles G Drake, Jamey Weichert, Douglas G McNeel
Androgen deprivation is the primary therapy for recurrent prostate cancer, and agents targeting the androgen receptor (AR) pathway continue to be developed. Because androgen-deprivation therapy (ADT) has immmunostimulatory effects as well as direct antitumor effects, AR-targeted therapies have been combined with other anticancer therapies, including immunotherapies. Here, we sought to study whether an antigen-specific mechanism of resistance to ADT (overexpression of the AR) may result in enhanced AR-specific T-cell immune recognition, and whether this might be strategically combined with an antitumor vaccine targeting the AR...
October 19, 2017: Cancer Immunology Research
https://www.readbyqxmd.com/read/29042604/placenta-specific1-plac1-is-a-potential-target-for-antibody-drug-conjugate-based-prostate-cancer-immunotherapy
#11
Mohammad-Reza Nejadmoghaddam, Amir-Hassan Zarnani, Ramin Ghahremanzadeh, Roya Ghods, Jafar Mahmoudian, Maryam Yousefi, Mahboobeh Nazari, Mohammad Hossein Ghahremani, Maryam Abolhasani, Ali Anissian, Morteza Mahmoudi, Rassoul Dinarvand
Our recent findings strongly support the idea of PLAC1 being as a potential immunotherapeutic target in prostate cancer (PCa). Here, we have generated and evaluated an anti-placenta-specific1 (PLAC1)-based antibody drug conjugate (ADC) for targeted immunotherapy of PCa. Prostate cancer cells express considerable levels of PLAC1. The Anti-PLAC1 clone, 2H12C12, showed high reactivity with recombinant PLAC1 and selectivity recognized PLAC1 in prostate cancer cells but not in LS180 cells, the negative control. PLAC1 binding induced rapid internalization of the antibody within a few minutes which reached to about 50% after 15 min and almost completed within an hour...
October 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29032188/genito-urinary-genomics-and-emerging-biomarkers-for-immunomodulatory-cancer-treatment
#12
REVIEW
Thomas Gevaert, Rodolfo Montironi, Antonio Lopez-Beltran, Geert Van Leenders, Yves Allory, Dirk De Ridder, Frank Claessens, Mark Kockx, Murat Akand, Steven Joniau, George Netto, Louis Libbrecht
Immunotherapy is gradually becoming a key factor in the therapeutic algorithm for patients with genito-urinary (GU) cancers at different stages of disease. Robust and reliable biomarkers are crucial for an appropriate inclusion of patients in clinical trials and for a reliable patient selection for treatments with immunomodulatory drugs. The increasing knowledge on the genomic landscape of GU cancers supports stratification of patients for targeted therapies. This review focusses on emerging biomarkers and the role of genomics in predicting clinical benefit to immunomodulatory agents in GU cancers...
October 12, 2017: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/29028078/a-natural-pharma-standard-supplement-formulation-to-control-treatment-related-toxicity-and-oxidative-stress-in-genitourinary-cancer-a-preliminary-study
#13
A Ledda, G Belcaro, M Dugall, R Luzzi, M Hosoi, B Feragalli, R Cotellese, V Cosentino, M Cosentino, R Eggenhoffner, M Pellizzato, A Fratter, L Giacomelli
OBJECTIVE: Oncological treatments are associated with toxicities that may decrease compliance to treatment in most genitourinary cancer patients. Supplementation with pharmaceutical-standardized supplement may be a supplementary method to control the side effects after chemo- and radiotherapy and the increased oxidative stress associated to treatments. This registry study evaluated a natural combination of supplements containing curcumin, cordyceps, and astaxanthin (Oncotris™) used as supplementary management in genitourinary cancer patients who had undergone oncological therapy...
September 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28971750/the-synergy-between-ionizing-radiation-and-immunotherapy-in-the-treatment-of-prostate-cancer
#14
Niranjan J Sathianathen, Suprita Krishna, Badrinath R Konety, Thomas S Griffith
There has been a surge in the use of immunotherapy for genitourinary malignancies. Immunotherapy is an established treatment for metastatic renal cell carcinoma and nonmuscle invasive bladder cancer, but its potential for treating prostate cancer (PCa) remains under investigation. Despite reported survival benefits, no published Phase III PCa trials using immunotherapy only as a treatment has demonstrated direct antitumor effects by reducing prostate-specific antigen levels. Subsequently, the thought of combining immunotherapy with other treatment modalities has gained traction as a way to achieving optimal results...
September 2017: Immunotherapy
https://www.readbyqxmd.com/read/28971747/expression-analysis-of-cancer-testis-genes-in-prostate-cancer-reveals-candidates-for-immunotherapy
#15
Sepideh Faramarzi, Soudeh Ghafouri-Fard
Prostate cancer is a prevalent disorder among men with a heterogeneous etiological background. Several molecular events and signaling perturbations have been found in this disorder. Among genes whose expressions have been altered during the prostate cancer development are cancer-testis antigens (CTAs). This group of antigens has limited expression in the normal adult tissues but aberrant expression in cancers. This property provides them the possibility to be used as cancer biomarkers and immunotherapeutic targets...
September 2017: Immunotherapy
https://www.readbyqxmd.com/read/28967901/mobilan-a-recombinant-adenovirus-carrying-toll-like-receptor-5-self-activating-cassette-for-cancer-immunotherapy
#16
V Mett, E A Komarova, K Greene, I Bespalov, C Brackett, B Gillard, A S Gleiberman, I A Toshkov, S Aygün-Sunar, C Johnson, E Karasik, M Bapardekar-Nair, O V Kurnasov, A L Osterman, P S Stanhope-Baker, C Morrison, M T Moser, B A Foster, A V Gudkov
Toll-like receptor 5 (TLR5) is considered an attractive target for anticancer immunotherapy. TLR5 agonists, bacterial flagellin and engineered flagellin derivatives, have been shown to have potent antitumor and metastasis-suppressive effects in multiple animal models and to be safe in both animals and humans. Anticancer efficacy of TLR5 agonists stems from TLR5-dependent activation of nuclear factor-κB (NF-κB) that mediates innate and adaptive antitumor immune responses. To extend application of TLR5-targeted anticancer immunotherapy to tumors that do not naturally express TLR5, we created an adenovirus-based vector for intratumor delivery, named Mobilan that drives expression of self-activating TLR5 signaling cassette comprising of human TLR5 and a secreted derivative of Salmonella flagellin structurally analogous to a clinical stage TLR5 agonist, entolimod...
October 2, 2017: Oncogene
https://www.readbyqxmd.com/read/28966917/advances-on-immunotherapy-in-genitourinary-and-renal-cell-carcinoma
#17
Gregory P Botta, Eric Granowicz, Carrie Costantini
Genitourinary (GU) cancers are a group of epithelial malignancies associated with the organs involved in the excretion of urine. Renal cell, urothelial, and prostatic carcinoma are the overwhelming subtypes diagnosed by oncologists. Each of these was traditionally treated surgically when local and non-invasive. When these carcinomas spread, invade, or metastasize, surgical control lacks in efficacy. Chemotherapeutic regimens have been implemented for decades and have increased overall survival but many patients progress...
February 2017: Translational Cancer Research
https://www.readbyqxmd.com/read/28948333/phase-i-ii-trial-of-dendritic-cell-based-active-cellular-immunotherapy-with-dcvac-pca-in-patients-with-rising-psa-after-primary-prostatectomy-or-salvage-radiotherapy-for-the-treatment-of-prostate-cancer
#18
Jitka Fucikova, Michal Podrazil, Ladislav Jarolim, Pavla Bilkova, Michal Hensler, Etienne Becht, Zdenka Gasova, Jana Klouckova, Jana Kayserova, Rudolf Horvath, Anna Fialova, Katerina Vavrova, Klara Sochorova, Daniela Rozkova, Radek Spisek, Jirina Bartunkova
OBJECTIVE: Immunotherapy of cancer has the potential to be effective mostly in patients with a low tumour burden. Rising PSA (prostate-specific antigen) levels in patients with prostate cancer represents such a situation. We performed the present clinical study with dendritic cell (DC)-based immunotherapy in this patient population. MATERIALS AND METHODS: The single-arm phase I/II trial registered as EudraCT 2009-017259-91 involved 27 patients with rising PSA levels...
September 25, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28935774/immunotherapy-a-new-and-old-approach-to-treatment-of-soft-tissue-and-bone-sarcomas
#19
REVIEW
Michael J Nathenson, Anthony P Conley, Edward Sausville
Soft tissue and bone sarcomas are a rare and heterogeneous form of cancer. With standard of care treatment options including surgery, radiation, and chemotherapy, the long-term survival is still low for high-risk soft tissue sarcoma patients. New treatment strategies are needed. Immunotherapy offers a new potential treatment paradigm with great promise. Immunotherapy of soft tissue sarcomas dates back to Dr. Coley's first use of toxins in the late 1800s. A variety of strategies of immunotherapy have been tried in soft tissue and bone sarcomas, including various vaccines and cytokines, with limited success...
September 21, 2017: Oncologist
https://www.readbyqxmd.com/read/28931402/recent-advances-of-bispecific-antibodies-in-solid-tumors
#20
REVIEW
Shengnan Yu, Anping Li, Qian Liu, Xun Yuan, Hanxiao Xu, Dechao Jiao, Richard G Pestell, Xinwei Han, Kongming Wu
Cancer immunotherapy is the most exciting advancement in cancer therapy. Similar to immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T), bispecific antibody (BsAb) is attracting more and more attention as a novel strategy of antitumor immunotherapy. BsAb not only offers an effective linkage between therapeutics (e.g., immune effector cells, radionuclides) and targets (e.g., tumor cells) but also simultaneously blocks two different oncogenic mediators. In recent decades, a variety of BsAb formats have been generated...
September 20, 2017: Journal of Hematology & Oncology
keyword
keyword
60735
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"